Business Wire

A2RL

25.7.2024 08:31:32 CEST | Business Wire | Press release

Share
A2RL Soars to New Heights: Launches Autonomous Drone Racing Championship Worth US $1Mn Prize Pool

The Abu Dhabi Autonomous Racing League (A2RL), which made its impressive debut this April at the Yas Marina Circuit, has announced the next phase of its challenge with the Drone Champions League (DCL), the world's premier professional drone racing organization. Building on the success of its inaugural event, the A2RL Drone Race continues to advance the frontiers of autonomous technology, merging human skill with innovative advancements in autonomous flight.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724188405/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Abu Dhabi Autonomous Racing League (A2RL) x Drone Champions League (DCL) (Graphic: AETOSWire)

The Autonomous Drone Race will bring together teams from across the globe, welcoming established drone racing teams, research institutions and enthusiastic 'rookies.' All competitors will vie for a thrilling prize purse of US$1million, as they strive to achieve maximum agility and speed while successfully maneuvering through objects in the way. Registration is now open at a2rl.io, and interested teams are invited to apply for the competition. All entries will undergo a rigorous selection process to identify the successful competing teams. Those who pass the screening will be invited to participate in a series of tasks that will allow the judging panel to assess the teams' proficiency in using an open-source simulator to fly a drone autonomously. The grand finale will be held in April 2025, where the winner will be determined.

Organized by ASPIRE, A2RL integrates artificial intelligence (AI), autonomy and extreme sports to push the boundaries of future mobility and is spotlighted as the largest autonomous racing league in the world. The A2RL extreme autonomous drone race will see competing researchers program drones to navigate through a sequence of gates, avoiding obstacles, using onboard sensors and computational power. The main goal of the race is to set a benchmark for achieving maximum innovation in algorithms while using minimal sensor technology in complex environments.

As with all grand challenges, the A2RL Drone Challenge will also include a STEM focus and high-school students will be welcome to be a part of the competition.

Announcing the new competition, H.E. Faisal Al Bannai, Secretary General of ATRC, said: “It's only when you experiment in extreme conditions that you really discover new boundaries or breakthroughs in science. We’re inspiring global collaboration, driving technological progress, and creating a future where autonomous solutions transform industries and improve lives.”

Stephane Timpano, CEO at ASPIRE, said: “This is an exciting evolution of our A2RL extreme racing series. DCL is a like-minded partner with years of invaluable drone racing experience. Together, we are not only adding a new autonomous dimension to drone racing but are also demonstrating the limitless possibilities of unmanned aerial vehicles through this competition.”

Markus Stampfer, Executive Chair of Drone Champions AG, the organizer of the Drone Champions League (DCL), said: “At DCL, our mission has always been to push the boundaries of drone racing. Having successfully merged the worlds of virtual and physical drone racing, partnering with ASPIRE to advance autonomous drone flying is a natural next step for us. We are thrilled to bring our extensive experience and expertise to this pioneering competition, supporting ASPIRE with the knowledge we've gained from years of developing race drones and working with the world's best drone pilots.”

By advancing drone technology, this race aims to make drone usage accessible for all countries, ultimately reducing costs and driving innovation across industries such as health and logistics.

For media enquiries please contact: comms@a2rl.io or ATRC@edelman.com

Twitter

LinkedIn

Instagram

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724188405/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI28.4.2026 15:22:00 CEST | Press release

Healthcare and life sciences leaders are advancing AI with caution—fragmentation, capability gaps, and execution challenges are slowing enterprise-wide impact AI is already embedded across healthcare and life sciences. Most organizations are deploying it, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428872907/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. HTEC, a global AI‑first provider of software and hardware design a

JPMorganChase Named First-Ever Global Banking Partner of the Olympic Games28.4.2026 15:00:00 CEST | Press release

International Olympic Committee and JPMorganChase Announce Landmark Global Olympic Partnership The International Olympic Committee (IOC) and JPMorganChase today announced a landmark Worldwide Olympic Partnership, making JPMorganChase the first Global Banking Partner in Olympic history. The partnership includes the Los Angeles 2028 Olympic and Paralympic Games (LA28 Games) and the French Alps 2030 Olympic and Paralympic Winter Games. The firm has also reached an agreement with LA28 to become the Official Bank of Team USA and LA28, and a Founding Partner of the LA28 Games. The partnership reflects a shared commitment to ambition and excellence, and places athletes and communities at its core. Kirsty Coventry, President of the IOC, commented: “JPMorganChase is the first Global Partner from the banking sector in Olympic history, and we are proud to welcome them to the Worldwide Olympic Partner programme. This partnership reflects our shared values of ambition, excellence and will support t

BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs28.4.2026 15:00:00 CEST | Press release

BlueSnap, powered by Payroc, today announced the availability of local acquiring in New Zealand, expanding its global payment orchestration capabilities and enabling businesses to process transactions domestically. Local acquiring allows businesses with a legal entity in New Zealand to process payments through domestic acquiring banks rather than routing transactions cross-border. This helps increase authorization rates, reduce payment failures, and lower transaction costs, critical factors for businesses selling into the region. Why Local Acquiring in New Zealand Matters For B2B and B2C businesses operating globally, cross-border payments often lead to higher fees and lower approval rates. Building local acquiring infrastructure independently requires managing multiple bank relationships, compliance, and integrations, making it costly and complex. BlueSnap simplifies this by providing local acquiring through a single platform, allowing businesses with a legal entity in New Zealand to

Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release

Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release

CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye